Scrip
Catalyst continues with anti-addiction drug despite Phase II failure
06 October 2009
Asher Mullard
Please Login to read the full article.
06 October 2009
Asher Mullard
Catalyst Pharmaceutical Partners will continue developing its CPP-109 (vigabatrin) anti-addiction drug after reporting that a recent Phase II failure in cocaine addicted patients was likely due to unexpectedly low compliance.
Post hoc analysis of the trial, along with data from a proof-of-concept...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
